Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis
Summary
Today, the company announced a 9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gr\xfcnderfonds (HTGF) to advance the development of novel therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF).IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. Niklas Czeloth, Investment Manager at BIVF and board member at Refoxy reiterates the need for novel approaches in tackling this disease. HTGF is proud to continue to invest in promising new drug targets and help bring this urgently needed treatment closer to IPF patients, explains Christian Kannemeier, Senior Investment Manager at HTGF.About Refoxy Pharmaceuticals GmbHRefoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. The BIVF seeks significant improvements in patient care through groundbreaking scientific findings and their clinical implementation, building long-term relationships with scientists and entrepreneurs. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.